Evidence map›Paper›PMID 33160327›Full record

ArticleBMC public health2020

Gridlock from diagnosis to treatment of multidrug resistant tuberculosis (MDR-TB) in Tanzania: patients' perspectives from a focus group discussion.

Stellah G Mpagama, Mangi J Ezekiel, Peter M Mbelele, Anna M Chongolo, Gibson S Kibiki, Kristen Petros de Guex, Scott K Heysell

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Stellah G MpagamaKibong'oto Infectious Diseases Hospital -Sanya Juu Siha/Kilimanjaro Clinical Research Institute Kilimanjaro Tanzania, Mae Street, Lomakaa road, Siha Kilimanjaro, Tanzania. sempagama@yahoo.com.ORCID http://orcid.org/0000-0002-0660-6930
Mangi J EzekielMuhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Peter M MbeleleKibong'oto Infectious Diseases Hospital -Sanya Juu Siha/Kilimanjaro Clinical Research Institute Kilimanjaro Tanzania, Mae Street, Lomakaa road, Siha Kilimanjaro, Tanzania.
Anna M ChongoloKibong'oto Infectious Diseases Hospital -Sanya Juu Siha/Kilimanjaro Clinical Research Institute Kilimanjaro Tanzania, Mae Street, Lomakaa road, Siha Kilimanjaro, Tanzania.
Gibson S KibikiEast African Health Research Commission, Bujumbura, Burundi.
Kristen Petros de GuexDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Scott K HeysellDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Kilimanjaro Christian Medical Centre · TZUniversity of Virginia · USMuhimbili University of Health and Allied Sciences · TZ

Funding

Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and AdultsR01AI137080 · NIAID · UNIVERSITY OF VIRGINIA · PI Scott K Heysell, Leonid Kagan · 2018 to 2026
$6.3M
Diagnostics and Pharmacotherapy for Severe Forms of TBU01AI115594 · NIAID · UNIVERSITY OF VIRGINIA · PI HEYSELL, SCOTT K, HOUPT, ERIC R · 2015 to 2019
$3.0M
European and Developing Countries Clinical Trials Partnership SF1463 - REMODEL-TZNIAID NIH HHS R01 AI137080NIAID NIH HHS U01 AI115594TDR, the Special Programme for Research and Training in Tropical Diseases, co-sponsored by UNICEF, UNDP, the World Bank and WHO Project ID B40121
6 · The paper itself

Abstract

backgroundMolecular diagnostics have revolutionized the diagnosis of multidrug resistant tuberculosis (MDR-TB). Yet in Tanzania we found delay in diagnosis with more than 70% of MDR-TB patients having a history of several previous treatment courses for TB signaling prior opportunities for diagnosis. We aimed to explore patients' viewpoints and experiences with personal and socio-behavioral obstacles from MDR-TB diagnosis to treatment in an attempt to understand these prior findings.

methodsThe study was conducted in December 2016 with MDR-TB patients admitted at Kibong'oto Infectious Diseases Hospital. A qualitative approach deploying focus group discussions (FGDs) was used to gather information. Groups were sex aggregated to allow free interaction and to gauge gender specific issues in the social and behavioral contexts. The FGDs explored pathways and factors in the service delivery that may have contributed in the delay in accessing MDR-TB diagnostics and/or treatment. Collected data were coded, categorized and thematically interpreted.

resultsForty MDR-TB patients participated in six FGDs. Challenges and barriers contributing to the delay in accessing MDR-TB diagnosis to treatment were as follows: 1) Participants had a different understanding of MDR-TB that led to seeking services outside the conventional health system; 2) Socio-economic adversity made health-seeking behavior difficult and often unproductive; 3) In the health system, challenges included inadequacy of MDR-TB diagnostic centers, lack of knowledge on behalf of health care providers to consider MDR-TB and order appropriate diagnostics; 4) The specimen referral system for early diagnosis of MDR-TB was inefficient. Non-adherence of TB patients to first-line anti-TB drugs prior to MDR-TB diagnosis, given the multitude of barriers discussed, was coupled with both intentional and unintentional non-adherence of health care providers to international standards of TB care.

conclusionPatient-centered strategies bridging communities and the health system are urgently required for optimum MDR-TB control in Tanzania.

Indexed as

Tuberculosis, Multidrug-ResistantAntitubercular AgentsFocus GroupsHealth PersonnelHumansSurveys and QuestionnairesTanzaniaAntitubercular AgentsFocus group discussionHealth care workersHealth systemsImplementationMolecular diagnosticsMultidrug resistant tuberculosis (MDR-TB)Qualitative research

Identifiers

PMID33160327
PMCPMC7648291
OpenAlexW3102646786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.